We sought comment on all elements of the proposed market-based data collection for cost reporting periods ending on or after January 1, 2026, and market-based methodology for estimating the MS-DRG relative weights beginning in FY 2029
Duration of benefit, safety and adherence should also be assessed in future studies of GLP-1 RMs for use in dumping syndrome post MBS, as well as broader research such as equity, cessation of treatment effects and perioperative management
If youre considering starting or switching medications, it helps to understand the differences between common options
The resulting data were analyzed using the 2 -CT method
However, no clinical data exists on switching between these specific drugs
Let the medication reach room temperature This is the single most impactful change you can make